Business
PRTC: New IPF Data Show Switch Patients Stabilized
PRTC: New IPF Data Show Switch Patients Stabilized.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n29 September 2025\nPureTech Health plc\n \nPureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF\n \nPatients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability\n \nFindings further substantiate safety and efficacy results from the randomized, placebo- and active-controlled 26-week trial and highlight opportunity to address patients inadequately served by current therapies\n \nRegulatory engagement underway; update on Phase 3 trial design expected in Q4 2025\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) in people living with idiopathic pulmonary fibrosis (IPF). These new results showed that participants who completed 26 weeks of placebo or pirfenidone treatment in the randomized portion of the trial and then switched to deupirfenidone for an additional 26 weeks in the OLE achieved stabilization of lung function. These findings, delivered in a late-breaking oral presentation at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, Netherlands, highlight the potential for deupirfenidone to become a new standard of care for the treatment of IPF.\n \n\"The blinded portion of the ELEVATE trial challenged the perspective that the biggest opportunity for new therapies in IPF is improved safety, by showing that treatment with deupirfenidone 825 mg three times a day can achieve lung function stabilization with favorable tolerability. The initial 52-week extension data then raised the bar by demonstrating that this effect with deupirfenidone was durable,\" said Argyrios E. Tzouvelekis, M.D., Ph.D., University of Patras, Greece, and presenting investigator at ERS 2025. \"Now we are seeing that two additional patient cohorts who experienced lung function decline in Part A of the trial achieved stabilization once switched to deupirfenidone. These findings reinforce that the...